T80.319 ABO incompatibility with hemolytic transfusion reaction, unspecified

Name of the Condition

• ABO incompatibility with hemolytic transfusion reaction, unspecified.

Summary

This condition describes an adverse immune reaction resulting from the transfusion of blood or blood products with incompatible ABO antigens, leading to hemolysis (destruction of red blood cells). It is a serious complication that can cause systemic effects, including organ damage and hemodynamic instability. The reaction is driven by pre-existing antibodies in the recipient that target antigens on the transfused red blood cells. The "unspecified" designation indicates the reaction type is not further classified.

Causes

ABO incompatibility reactions result from the transfusion of blood or blood products containing ABO antigens that do not match the recipient's blood type. This mismatch triggers an immune response, where the recipient's antibodies bind to the donor red blood cells, leading to their destruction (hemolysis). The reaction can occur with red blood cells, plasma, or platelets if ABO compatibility is not maintained during transfusion.

Risk Factors

• Transfusion of blood products without proper ABO typing or crossmatching
• Emergency transfusions where typing may be delayed
• Human error in blood product labeling or administration
• Use of pooled plasma products with mixed ABO types
• Transfusion of platelets or plasma from donors with incompatible ABO antigens

Symptoms

• Fever, chills, or rigors
• Flank pain or back pain
• Hemoglobinuria (dark urine)
• Hypotension or tachycardia
• Dyspnea or chest pain
• Nausea or vomiting

Diagnosis

Diagnosis involves clinical assessment of symptoms following transfusion, laboratory testing to confirm hemolysis (e.g., elevated bilirubin, decreased haptoglobin, hemoglobinuria), and verification of ABO incompatibility through blood typing and crossmatching. Additional tests may include direct antiglobulin testing (Coombs test) to detect antibody-coated red blood cells.

Treatment Options

Treatment focuses on stopping the transfusion immediately, providing supportive care (e.g., fluids, vasopressors for hypotension), and managing complications such as renal failure or disseminated intravascular coagulation. Corticosteroids or other immunosuppressants may be used in severe cases. Exchange transfusion or dialysis may be necessary for significant hemolysis or organ dysfunction.

Prognosis and Follow-Up

Prognosis depends on the severity of the reaction and promptness of treatment. Mild cases may resolve with supportive care, while severe reactions can lead to organ failure or death. Follow-up includes monitoring for delayed complications, such as renal impairment or recurrent hemolysis, and ensuring proper blood typing protocols are reinforced to prevent recurrence.

Complications

• Acute kidney injury or renal failure
• Disseminated intravascular coagulation (DIC)
• Shock or multiorgan failure
• Neurologic sequelae (e.g., stroke)
• Death (in severe cases)

Lifestyle & Prevention

Prevention relies on strict adherence to blood typing and crossmatching protocols before transfusion. Double-checking blood product labels and patient identification reduces human error. Using leukoreduced or washed blood products may minimize reactions in high-risk patients. Educating staff on emergency protocols for suspected incompatibility is critical.

When to Seek Professional Help

Seek immediate medical attention if symptoms of a transfusion reaction occur, such as fever, chills, pain, or changes in urine color, during or after a blood transfusion. Prompt intervention is essential to mitigate severe complications.

Tips for Medical Coders

Code T80.319 is used when ABO incompatibility with hemolytic transfusion reaction is documented as unspecified. Ensure the medical record supports the presence of a hemolytic reaction and ABO incompatibility without further specification of encounter type or sequela. Document any additional details (e.g., severity, treatment) to support coding accuracy.